Quantcast

Latest Fluticasone/salmeterol Stories

2010-11-01 21:30:13

Benefits outweigh risks for asthmatics, but COPD patients should think twice Patients taking inhaled corticosteroids are at increased risk of developing type 2 diabetes, and more so with higher doses, say researchers at the Jewish General Hospital's Lady Davis Institute for Medical Research (LDI) In Montreal. The risk is of special concern for patients suffering from chronic obstructive pulmonary disorder (COPD), and much less significant for asthmatics. "These medications are very effective...

2010-08-31 08:45:00

BURLINGTON, Mass., Aug. 31 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2019, an expanding aging population and increases in diagnosis and drug treatment will fuel steady 4.6 percent annual growth in the chronic obstructive pulmonary disease (COPD) drug market. The Pharmacor 2010 findings from the topic entitled Chronic Obstructive Pulmonary Disease reveal that the COPD drug...

2010-08-24 10:30:00

WALTHAM, Mass., Aug. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that some surveyed physicians indicate that they will decrease their overall prescribing of long-acting beta2 agonists (LABA)/inhaled corticosteroids (ICS) combination therapies over the next 12 months for the treatment of asthma in response to the U.S. Food and Drug Administration's new safety controls for LABA-containing...

2010-07-16 13:22:00

SILVER SPRING, Md., July 16 /PRNewswire-USNewswire/ -- The FDA is warning the public that certain Advair Diskus inhalers stolen from a distribution warehouse in 2009 have been found in some pharmacies. The safety and effectiveness of the stolen inhalers cannot be assured and they should not be used. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Advair Diskus (fluticasone propionate and salmeterol inhalation powder)...

2010-06-02 17:05:00

RESEARCH TRIANGLE PARK, N.C., June 2 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that it has received a letter from the U.S. Food and Drug Administration directing revisions to product labeling for its respiratory products Serevent® and Advair®. The letter concludes discussions between GSK and the agency following FDA advisory committee meetings regarding the safety profile of long-acting beta2-agonists in the treatment of...

2010-04-26 08:45:00

WALTHAM, Mass., April 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite increased competition from several emerging agents, GlaxoSmithKline's Advair will remain surveyed pulmonologists' and primary care physicians' (PCPs) favored fixed-dose long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination inhaler through 2013 for the treatment of asthma and chronic obstructive...

2010-02-18 16:54:00

RESEARCH TRIANGLE PARK, N.C., Feb. 18 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) is reviewing label changes proposed today by the US Food and Drug Administration (FDA) for asthma medications containing long-acting beta-agonists (LABAs), such as GSK's Advair (salmeterol / fluticasone propionate). GSK and makers of the other affected medicines containing LABAs have 30 days to agree with the proposed changes or state why they are not warranted. "We will work with FDA to ensure...

2010-02-18 11:00:00

SILVER SPRING, Md., Feb. 18 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that drugs in the class of long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma in children or adults. Manufacturers will be required to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medications. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) These new...

2010-02-08 10:55:00

WALTHAM, Mass., Feb. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected launch this year for the treatment of asthma, Merck's formoterol/mometasone will garner peak year sales of more than $250 million in the United States, France, Germany, Italy, Spain and the United Kingdom. The Pharmacor 2010 finding from the topic entitled Asthma reveals that formoterol/mometasone, a...

2010-02-02 07:00:00

WALTHAM, Mass., Feb. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim/Pfizer's Spiriva will retain Decision Resources' proprietary clinical gold standard status for the treatment of chronic obstructive pulmonary disease (COPD) through 2018. While some drugs in development for COPD hold promise, most have less favorable efficacy, safety and tolerability, and/or delivery...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'